8-K: Zeo ScientifiX Enters Joint Venture with BioXtek, Appoints New Chief Scientific and Technology Officer

Zeo ScientifiX, Inc. announces a joint venture with BioXtek, LLC and the appointment of Dr. Peter A. M. Everts as Chief Scientific and Technology Officer.

Summary

• Zeo ScientifiX, Inc. has entered into a binding memorandum of understanding with BioXtek, LLC to form a joint venture focused on developing, manufacturing, marketing, and funding biologic regenerative therapeutics.
• The joint venture includes Zeo relocating its operations to BioXtek's facility in Pompano Beach, Florida by May 31, 2025.
• BioXtek will provide technical, quality control, and shipping personnel to Zeo, as well as access to clean rooms.
• BioXtek may become the exclusive contract manufacturer for Zeo's HAF and peripheral blood derived products, subject to quality control and regulatory compliance.
• Zeo and BioXtek will establish a jointly-owned (50/50) special purpose entity (SPE) to develop and commercialize products, including BioXtek's Membrane Products, and pursue FDA approval.
• Both companies will contribute intellectual property to the SPE and work to secure funding for the SPE's business.
• The SPE will become the exclusive distributor of BioXtek's Membrane Products, with some exceptions for BioXtek's current customers.
• Effective February 7, 2025, Dr. Peter A. M. Everts was appointed as the Company's Chief Scientific and Technology Officer.
• Dr. Everts' employment agreement includes a base salary of $220,000 for the first year and $235,000 per annum for each subsequent year, subject to potential adjustments.
• Dr. Everts was granted an option to purchase 25,000 shares of common stock at $3.05 per share, vesting over two years.
• Dr. Everts may also receive a performance bonus based on criteria set by the Board of Directors.

Sentiment

Score: 7

Explanation: The announcement of a joint venture and the appointment of a new CSTO are positive developments for the company. However, the success of the joint venture is contingent on securing funding and obtaining regulatory approvals.

Positives

• The joint venture with BioXtek provides Zeo with access to manufacturing facilities, technical expertise, and potential revenue streams from BioXtek's Membrane Products.
• The appointment of Dr. Everts as CSTO brings significant experience in regenerative and Ortho biological applications and technologies to Zeo.
• The relocation to BioXtek's facility is expected to create operating efficiencies.
• The joint venture aims to obtain FDA approval for new products, which could significantly increase their market value.

Negatives

• The success of the joint venture depends on the ability of Zeo and BioXtek to agree upon and execute definitive agreements.
• The joint venture requires securing funding for the SPE Business.
• Dr. Everts' employment is 'At Will', meaning his employment can be terminated at any time, for any reason or no reason at all and with or without Cause.

Risks

• Failure to secure funding for the SPE Business could hinder the development and commercialization of new products.
• Delays in relocating operations to BioXtek's facility could impact the timeline for the joint venture.
• The joint venture's success is contingent on obtaining FDA approval for new products, which is subject to regulatory uncertainty.
• The market for regenerative therapeutics is competitive, and the joint venture may face challenges in gaining market share.

Future Outlook

The joint venture aims to develop and commercialize regenerative medicine products, including BioXtek's Membrane Products, and to obtain FDA approval for these products. Zeo expects to achieve operating efficiencies through the relocation of its operations to BioXtek's facility.

Industry Context

The regenerative medicine market is growing, with increasing demand for biologic therapies for wound care, surgical applications, and musculoskeletal disorders. This joint venture allows Zeo to leverage BioXtek's manufacturing capabilities and market presence in this space.

Comparison to Industry Standards

• Comparable companies in the regenerative medicine space include Organogenesis, MiMedx, and Vericel.
• BioXtek's cGMP, cGTP and AATB compliant 11,000 square foot manufacturing facility in Pompano Beach, Florida is a significant asset, allowing for in-house manufacturing and quality control.
• The 50/50 joint venture structure is a common approach for companies seeking to share resources and expertise in developing new products.

Management Changes

Stakeholder Impact

• Shareholders may benefit from the potential for increased revenue and profitability through the joint venture.
• Employees may experience changes in their work environment due to the relocation of operations.
• Customers may have access to new and improved regenerative medicine products.
• Suppliers may see increased demand for their products and services.

Next Steps

• Zeo and BioXtek will work towards finalizing definitive agreements documenting the Joint Venture.
• Zeo will relocate its operations to BioXtek's facility by May 31, 2025.
• The SPE will pursue the development and commercialization of agreed-upon products, including BioXtek's Membrane Products.
• The SPE will conduct and complete all required clinical trials with the goal of obtaining FDA approval.

Key Dates

Keywords

Joint Venture, BioXtek, Regenerative Therapeutics, Chief Scientific and Technology Officer, HAF Products, Membrane Products, FDA Approval, Peter Everts, Zeo ScientifiX